To describe the use of subcutaneous (s.c.) metoclopramide in the outpatient treatment of hyperemesis gravidarum.
Hyperemesis gravidarum is characterized by intractable nausea and vomiting during pregnancy with concurrent disturbances of nutrition and fluid balances. While nausea and vomiting afflicts 60% to 70% of pregnant women, hyperemesis gravidarum is relatively uncommon, occurring in ϳ5 per 1000 pregnancies. 1 Ultimately, hyperemesis gravidarum accounts for ϳ4% to 7% of all antenatal hospital admissions and 30% of admissions before 20 weeks' gestation. 2 When patients experience hyperemesis gravidarum, there is significant disruption in their lives, and there is a high cost to society. In a review of hyperemesis gravidarum by Cowan, 3 women reported curtailing social contacts. They also reported that relationships with spouses and families were altered. Vellacott et al. 4 reported that 183 of 243 pregnant women experienced nausea and vomiting in pregnancy, and 47% of these women felt that their job efficiency was reduced. Gadsby et al. 1 have estimated that in England, some 8.6 million hours of paid employment and 5.8 million hours of housework are being lost through nausea and vomiting in pregnancy of all severities each year.
Traditionally, this condition has resulted in costly management and loss of productivity due to prolonged and/or recurrent hospital admissions, as well as physical and emotional sequela. According to the Healthcare Cost and Utilization Project (HCUP), the average charge for patients treated for ICD-9-CM 643.13 (Hyperemesis with Metabolic Disturbances-Antepartum) in the hospital is $1291.33 per day. 5 Studies looking at patients with hyperemesis gravidarum have reported frequent hospital admissions. 2, 6, 7 In one such study, 28% (39 of 140) of patients with hyperemesis gravidarum were admitted to the hospital 2.9 times on average (range 2 to 6 times). 6 Often, obstetricians have been faced with the challenge of effectively treating hyperemesis gravidarum while trying to keep their patients from being admitted to the hospital.
Due to the unknown etiology of hyperemesis gravidarum, attempted or recommended treatments are varied and unstructured. All obstetricians have been faced with the challenge of effectively treating hyperemesis gravidarum while trying to avoid further personal and familial disruption and financial burdens for the patient related to hospital admission. There is little in the literature describing the use of subcutaneous (s.c.) metoclopramide therapy for the treatment of severe nausea and vomiting during pregnancy. The purpose of this study is to describe the use of s.c. metoclopramide in patients diagnosed with hyperemesis gravidarum.
MATERIALS AND METHODS
Patients were identified from a nationwide perinatal database that contains information on women throughout the United States with high-risk pregnancies who were prescribed various outpatient management programs by their physicians. Patients included for analysis Original Article The diagnosis of hyperemesis gravidarum was made by each patient's individual physician and reported to the home care provider at referral for services. S.c. metoclopramide was not a first-line treatment. It was only prescribed after other treatments, such as phenothiazines, antihistamines, oral metoclopramide, dietary changes, and i.v. hydration had failed to resolve symptoms of hyperemesis. S.c. metoclopramide was initiated using a protocol that included an initial 10-mg loading dose administered either intramuscularly or i.v. followed by continuous s.c. administration using a portable, programmable micro-infusion pump (MiniMed 404SP; MiniMed Technologies, Sylmar, CA). S.c. metoclopramide therapy was initiated by a perinatal nurse either at the hospital, at the physician's office, or in the patient's home. The continuous infusion rate was titrated based on the patient's symptoms. Once the patient reported cessation of symptoms, the infusion rate was held constant. Patients were instructed to withhold oral feedings until symptoms abated. After dietary advancement, without resumption of nausea and vomiting, the continuous infusion rate was decreased as tolerated. All patients received individualized instruction on diet modification, infusion device operation, infusion site selection, initiation and care, and emergency procedures. In addition, all patients received daily, and as needed, telephone contact with a perinatal nurse. Additional home nursing visits occurred as needed.
Maternal characteristics and treatment information were analyzed. The primary outcome was resolution of hyperemesis symptoms during the treatment period. Data were reported as mean Ϯ SD or percentage as indicated.
RESULTS
There were 646 women identified with a diagnosis of hyperemesis gravidarum who received s.c. metoclopramide therapy. Maternal information is presented in Table 1 .The mean age was 28.0 Ϯ 5.3 years, and 27.4% were primigravid. There were 24 women with multiple gestations. The overall mean gestational age at start of s.c. metoclopramide was 11.0 Ϯ 4.1 weeks. The majority of patients (78.5%) started treatment in the first trimester of pregnancy. Overall, mean pregnancy weight loss per patient at initiation of s.c. metoclopramide was 5.2 pounds. Before the initiation of s.c. metoclopramide, 16% had received oral metoclopramide, 75% had received antiemetic medications other than metoclopramide, and 51.5% had been hospitalized at least once. The adjuvant treatments used before and after administration of s.c. metoclopramide are presented in Table 2 .
The location where metoclopramide therapy was initiated was documented for 569 patients; in 37.3% of patients, therapy was initiated in the hospital or physician's office, whereas 62.7% had therapy initiated in their home. The average effective maintenance dose was 1.28 mg/hour (30.8 mg/day). Within 48 hours of initiation of s.c. metoclopramide, 52.5% of women reported lessening of emesis, and 44.6% reported feeling less nauseous.
Side effect data are presented in Table 3 . The majority of patients (70.3%) experienced no side effects related to metoclopramide therapy. Of those 192 patients who reported side effects of treatment, 30 experienced extra-pyramidal symptoms, 31 reported lethargy, 68 reported site irritation, and 72 had agitation. Side effects were generally mild and were treated with oral or intramuscular diphenhydramine. Only five patients had side effectrelated emergency department or hospital admissions. A total of 46 women discontinued s.c. metoclopramide because of side effects. There were no reports of long-term sequela related to treatment with continuous s.c. metoclopramide.
Treatment outcomes are presented in Table 4 . The mean gestational age at discontinuation of s.c. metoclopramide was 15.0 Ϯ 5.4 weeks, with one-half of patients discontinuing therapy within 3.3 weeks of start. A total of 413 patients (63.9%) reported complete resolution of their hyperemesis gravidarum during treatment with continuous s.c. metoclopramide.
DISCUSSION
Women who experience hyperemesis gravidarum are a particularly challenging group of patients. There is a dramatic disruption of their personal and family life, as well as tangible and intangible losses in the home and in the workplace. Although mental processes are sometimes postulated to underlie severe nausea and vomiting in pregnancy, there is in all likelihood a complex interaction between physiological and emotional causative factors in women suffering from hyperemesis gravidarum. Fearfulness, irritability, lowered mood, and sleep disturbances are common accompaniments to severe nausea and vomiting in pregnancy. There are numerous theories on the etiology of nausea and vomiting in pregnancy, such as pressure on the diaphragm, atypical human chorionic gonadotropin levels or metabolism, various hormonal dysfunctions, liver abnormalities, gastric hypofunction, vitamin B deficiencies, excess fatigue, and many more. 8, 9 The cause of intractable vomiting, which leads to disturbed nutrition with weight loss, altered electrolyte balance, or dehydration (hyperemesis gravidarum), remains unknown and is a problem that is poorly understood and largely ignored in clinical research. Certain obstetric conditions have been associated with hyperemesis. These include multiple gestation, gestational trophoblastic disease, and certain fetal anomalies. 10 Unfortunately, because of the emphasis on the psychological component that may or may not influence hyperemesis, research in terms of physiological causes has been scarce.
Successful management of nausea and vomiting in pregnancy is dependent on a patient's willingness to accept the numerous theories and potential explanations of its etiology, plus the fact that the treatment may consist of many unrelated and potentially unorthodox strategies. 9, [11] [12] [13] [14] Unfortunately, women suffering from severe nausea and vomiting in pregnancy face many obstacles in obtaining treatment for their condition. There may well be a discrepancy between the caregiver's and a woman's impression of subjective sensations such as nausea. 15 Some physicians resort to very simplistic and ingrained interventions that meet with little or no success. 11, 16, 17 Some even totally reject nausea and vomiting in pregnancy as a disease state and refuse to treat it at all. 15, 16 Lack of patient education on nausea and vomiting in pregnancy is also a problem. Over half of the patients participating in one study were unaware of commonly used medications, coping strategies, nutrition-monitoring techniques, or other treatment options that were readily available. 16 Many providers who care for patients with nausea and vomiting in pregnancy or hyperemesis gravidarum still believe that it is a condition that is confined to the first trimester. However, reports have shown that these problems can persist well past the first trimester. 4, 16 In one study of 500 consecutive antenatal patients evaluated, 76% complained of nausea and vomiting in the first trimester, but only 27% had the symptoms resolved by week 12 of pregnancy. 4 In the second review, 47% of women with hyperemesis gravidarum had symptoms in the second or third trimester and 21% were actively ill throughout the entire pregnancy. 16 Historically, severe nausea and vomiting in pregnancy/hyperemesis gravidarum has required frequent and/or prolonged hospitalizations. 3, 6, 7, 16 Physicians caring for patients with hyperemesis gravidarum must keep in mind that control may be an issue and that hospitalization includes an assumption of a dependent role plus separation from home and family support. 3, 18 Published reports on home therapy versus hospitalization for hyperemesis gravidarum have described better treatment outcome, decreased recurrence, and less expense with home therapy. 7 When the frequent need for prolonged therapy is also taken into account, the case for home management of hyperemesis gravidarum becomes quite strong. 3, 6 The symptoms of hyperemesis gravidarum may undermine self esteem and seriously impact a woman's ability to fulfill her obligations. 15 These factors underscore the need for a treatment that allows women to feel in control and allows them to resume their familiar routine as quickly as possible. Dietary instructions may be more effective when given at home rather than in the stressful environment of the hospital. 3 As patient education is a vital component of therapy for hyperemesis gravidarum, the home care nurse can take advantage of this unique opportunity to provide individualized education in response to the observed environment. 19 Treatments for hyperemesis represent a wide spectrum of scientifically derived and empirical approaches. An incomplete list of treatments includes: rest, ingestion of placental extract, hormones, corticosteroids, vitamins, i.v. hydration, i.v. honey, electric current, relaxation techniques, hypnosis, acupressure, and nutritional counseling with dietary modification. 4, 9 In addition to all the previously mentioned modes of treatment, a wide variety of medications have also been used to treat patients with nausea and vomiting in pregnancy.
Many classes of drugs with differing mechanisms of action have been variably effective in controlling nausea and vomiting in pregnancy.
3,10 S.c. metoclopramide has been reported to be a successful treatment for gastroparesis 20 and chemotherapy-induced emesis. 21 Metoclopramide reduces nausea both directly and indirectly. It acts on the central chemoreceptor trigger zone and by increasing the tone at the esophageal-gastric junction decreases reflux. In addition, it shortens gastric emptying time. 3 Based on our review of the literature and on the results of our study, s.c. metoclopramide appears to be a safe and effective therapy for hyperemesis gravidarum. Although we acknowledge that the retrospective, descriptive, nonrandomized design of our analysis limits what may be concluded from our observations, historically, a rate of success equal to that reported here has been achieved largely through the use of multiple therapies/agents in sequence or in combination, often requiring prolonged or recurrent hospitalization. Using s.c. metoclopramide in the home environment should provide a clear economic advantage versus hospitalization. Finally, the added benefit for these stressed and disheartened patients of being treated in familiar surroundings with their family and support network readily available cannot be overestimated. Further studies are needed to evaluate the safety and efficacy of s.c. metoclopramide versus other treatments.
